Get the Stockscreener App
26.14
0.29%
-0.075
After Hours:
26.00
-0.145
-0.55%
Amphastar Pharmaceuticals Inc stock is traded at $26.14, with a volume of 233.27K.
It is down -0.29% in the last 24 hours and down -4.30% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$26.22
Open:
$26.25
24h Volume:
233.27K
Relative Volume:
0.60
Market Cap:
$1.20B
Revenue:
$722.68M
Net Income/Loss:
$134.71M
P/E Ratio:
9.7921
EPS:
2.67
Net Cash Flow:
$109.94M
1W Performance:
+0.56%
1M Performance:
-4.30%
6M Performance:
+22.46%
1Y Performance:
-27.66%
1-Day Range:
$26.10
$26.92
1-Week Range:
$25.42
$26.92
52-Week Range:
$20.39
$37.66
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
26.14 | 1.20B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
124.40 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.94 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.33 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.66 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
472.06 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
How Amphastar Pharmaceuticals Inc. (AMPH) Affects Rotational Strategy Timing - Stock Traders Daily
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? - sharewise.com
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving - Finviz
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin - Yahoo Finance
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth - MarketBeat
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead - Finviz
Aug Opening: Will Amphastar Pharmaceuticals Inc stock recover faster than peers2025 Price Targets & Smart Investment Allocation Tips - Bộ Nội Vụ
Earnings Recap: Will Amphastar Pharmaceuticals Inc stock pay special dividends2025 Big Picture & Capital Protection Trade Alerts - Bộ Nội Vụ
Amphastar licenses synthetic ACTH analog for inflammatory conditions By Investing.com - Investing.com Nigeria
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook With A 7.39% Upside Potential - DirectorsTalk Interviews
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today - Finviz
Amphastar Licenses ACTH Analog AMP-110 for North America - TipRanks
Amphastar Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110 - Contract Pharma
Amphastar licenses synthetic ACTH analog for inflammatory conditions - Investing.com
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound - ACCESS Newswire
New synthetic hormone treatment targets autoimmune and inflammatory conditions - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Could Be Riskier Than It Looks - 富途牛牛
The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight - Yahoo Finance
Is Amphastar Pharmaceuticals Inc. stock a smart buy before Fed meetingExit Point & Daily Profit Focused Screening - Улправда
(AMPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is Amphastar Pharmaceuticals (AMPH) Attractively Priced After Recent Share Price Weakness? - Sahm
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Trimmed by CX Institutional - MarketBeat
Why Amphastar Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - Улправда
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum - Sahm
Will Amphastar Pharmaceuticals Inc. stock benefit from AI adoption2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Amphastar Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Profit Report & High Return Trade Opportunity Guides - ulpravda.ru
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference - ACCESS Newswire
Amphastar Expands BAQSIMI® Distribution in Asia - MSN
Value Recap: Is Amphastar Pharmaceuticals Inc stock trading near support levels2025 Technical Patterns & Weekly Breakout Watchlists - moha.gov.vn
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc. - MarketBeat
What analysts say about Amphastar Pharmaceuticals Inc stockTake Profit Strategies & Outstanding Investment Portfolio - earlytimes.in
Amphastar Director Sells 16,679 Shares for $441,800 - AOL.com
Amphastar Pharmaceuticals Inc Stock Analysis and ForecastVolatility Index Analysis & Swing Trade Smarter With Data Insights - earlytimes.in
Will Amphastar Pharmaceuticals Inc. stock split again soonStock Screening Results & Make Confident Moves With Forecasting Models - bollywoodhelpline.com
Is Amphastar Pharmaceuticals Inc stock affected by interest rate hikesShort Setup & Reliable Intraday Trade Alerts - moha.gov.vn
How supply chain issues affect Amphastar Pharmaceuticals Inc. stockInstitutional Holding Changes & Minimal Investment Portfolio - bollywoodhelpline.com
Responsive Playbooks and the AMPH Inflection - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC - MarketBeat
Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals’ Resilient Q3 2025 Earnings Call - MSN
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a Potential 16.08% Upside for Investors - DirectorsTalk Interviews
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation - Sahm
Will Amphastar Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Community Trade Idea Sharing Platform - Улправда
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025? - Sahm
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):